Stealth’s lead investigational compound elamipretide targets the inner mitochondrial membrane, binds to cardiolipin and has been shown to improve mitochondrial function. It is being studied in rare diseases linked to mitochondrial dysfunction such as primary mitochondrial myopathy and Barth syndrome. Stealth will share lessons from the SPIMM 301 and TAZPOWER studies, explain how these results helped design the NuPOWER trial, describe how we think this product works and share information about their Expanded Access Program.
About the Speaker
Gene Kelly joined Stealth BioTherapeutics in 2014 and is currently the Executive Director of Medical Affairs. He has broad experience in pre-commercialization activities and has held leadership roles at both public and private biotechnology companies. Gene has worked closely with Mitochondrial Medicine Experts and Rare Disease Patient Advocacy Groups to gain insights that guide clinical development and disease awareness programs. He holds a bachelor’s degree in Pharmacy.